Amgen's erenumab passes Phase II chronic migraine test

Amgen Inc. (NASDAQ:AMGN) said erenumab ( AMG 334) met the primary endpoint of change in monthly migraine days vs. placebo in a Phase II study to prevent chronic migraine.

The biotech said 70 or 140 mg subcutaneous doses of erenumab administered once monthly each led to a significant 6.6-day reduction in monthly migraine days from baseline vs. 4.2 days for placebo. The study enrolled 667 patients who had about 18 migraine days per month at baseline. The primary endpoint compared baseline to the last four weeks of the 12-week treatment period. ...